The approval marks the sixth biosimilar to reference Stelara (ustekinumab), and it will be used to treat several immunology ...

Veterans with inflammatory bowel disease (IBD) prioritize shared decision-making, transparency, and individualized care in ...

On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and ...

Bevacizumab biosimilars have the potential to expand access and reduce costs without compromising patient outcomes in ...

In November 2024, Skyrizi surpassed Humira as AbbVie's top seller; calls for PBM transparency and biosimilar access reforms ...

The study findings demonstrate that the aflibercept biosimilar MYL-1701P is as effective and safe as the reference ...

Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption ...

Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by ...

Regulatory policies influence the availability of affordable biosimilars, with varying impacts across different jurisdictions ...

Although financial incentives introduced by Japan's 2022 health policy did not result in a reduction in overall drug costs, ...

The biosimilar ocrelizumab candidate (Xacrel) was found to be equivalent to the originator product (Ocrevus) in reducing the annualized relapse rate and showed comparable safety and efficacy over 96 ...